Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 417

Sort by

Sort Order Select

Journal Articles

A First-in-Human Dose Escalation Clinical Trial of Engineered Natural Killer Cell Therapy in Non-Small Cell Lung Cancer Patients Refractory to Immune Check Point Inhibitors

Miguel A Villalona, Lei Tian, Xiaochen Li, Joycelynne Michelle Palmer, Claudia Aceves, Hans Meisen, Catherine Cortez, Tim W Synold, Colt Egelston, Jeffery Vandeusen, Ivone Bruno, Lei Zhang, Eliezer Romeu-Bonilla, Omer Butt, Stephen J. Forman, Michael A Caligiuri, Jianhua Yu

Blood (2024) 144 (Supplement 1): 7206.

https://doi.org/10.1182/blood-2024-202132

Published: 2024

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Journal Articles

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Blood (2024) 144 (Supplement 1): 3534.

https://doi.org/10.1182/blood-2024-207125

Published: 2024

Journal Articles

Clonal Hematopoiesis and Venous Thromboembolism Risk in Lymphoma Patients Surviving Autologous Transplantation

Radhika Gangaraju, Yanjun Chen, Lindsey Hageman, Elizabeth Ross, Liton Francisco, David K Crossman, Purnima Singh, Alysia Bosworth, Daniel Weisdorf, Ravi Bhatia, Saro Armenian, Stephen J. Forman, Smita Bhatia

Blood (2024) 144 (Supplement 1): 14.

https://doi.org/10.1182/blood-2024-201067

Published: 2024

Journal Articles

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Blood (2024) 144 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2024-206169

Published: 2024

Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Blood (2024) 144 (Supplement 1): 524.

https://doi.org/10.1182/blood-2024-198749

Published: 2024

Journal Articles

TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2024) 144 (Supplement 1): 729.

https://doi.org/10.1182/blood-2024-208674

Published: 2024

Journal Articles

Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report

Nora Balas, Joshua Richman, Wendy Landier, Sadeep Shrestha, Katia J Bruxvoort, Lindsey Hageman, Qingrui Meng, Elizabeth Ross, Alysia Bosworth, Hok Sreng Te, F. Lennie Wong, Ravi Bhatia, Stephen J. Forman, Saro Armenian, Daniel Weisdorf, Smita Bhatia

Blood (2024) 144 (Supplement 1): 403.

https://doi.org/10.1182/blood-2024-204551

Published: 2024

Journal Articles

Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies - a BMT Survivor Study (BMTSS)

Blood (2024) 144 (Supplement 1): 5036.

https://doi.org/10.1182/blood-2024-204686

Published: 2024

Journal Articles

Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report

Blood (2024) 144 (Supplement 1): 5146.

https://doi.org/10.1182/blood-2024-204623

Published: 2024

Journal Articles

Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation

June-Wha Rhee, Sitong Chen, Raju Pillai, Alysia Bosworth, Artem Oganesyan, Liezl Atencio, Caitlyn Estrada, Mareen Kassabian, Lanie Lindenfeld, Scott R. Goldsmith, Michael Rosenzweig, Alex F. Herrera, Matthew Mei, Ryotaro Nakamura, F. Lennie Wong, Stephen J. Forman, Saro Armenian

Blood (2024) 144 (Supplement 1): 947.

https://doi.org/10.1182/blood-2024-200402

Published: 2024

Journal Articles

CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study

Blood (2024) 144 (Supplement 1): 966.

https://doi.org/10.1182/blood-2024-201784

Published: 2024

Journal Articles

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Xiuli Wang, Swetha Kambhampati, Alan Macias, Emanuela C Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (Supplement 1): 3127.

https://doi.org/10.1182/blood-2024-198416

Published: 2024

Journal Articles

Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report

Blood (2024) 144 (Supplement 1): 2338.

https://doi.org/10.1182/blood-2024-204642

Published: 2024

Journal Articles

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Tamer Othman, John H. Baird, Yan Wang, Stacy Pak, Ibrahim Aldoss, Ji-Lian Cai, Alexey Danilov, Tycel J. Phillips, Vaibhav Agrawal, Karamjeet S Sandhu, Matthew Mei, Paul B. Koller, Joycelynne Michelle Palmer, Stephen J. Forman, Lihua E. Budde, Ahmed Aribi

Blood (2024) 144 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2024-207085

Published: 2024

Journal Articles

Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Blood (2024) 144 (Supplement 1): 4935.

https://doi.org/10.1182/blood-2024-210956

Published: 2024

Journal Articles

Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies - a BMT Survivor Study (BMTSS)

Blood (2024) 144 (Supplement 1): 5053.

https://doi.org/10.1182/blood-2024-204662

Published: 2024

Journal Articles

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Blood (2023) 142 (Supplement 1): 4959.

https://doi.org/10.1182/blood-2023-187156

Published: 2023

Journal Articles

Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Scott R. Goldsmith, Geoffrey P. Shouse, F. Lennie Wong, Alysia Bosworth, Aleksi Iujuridze, Sitong Chen, June-Wha Rhee, Matthew G. Mei, Murali Janakiram, Myo Htut, Stephen J. Forman, Raju Pillai, L. Elizabeth Budde, Saro Armenian

Blood (2023) 142 (Supplement 1): 4814.

https://doi.org/10.1182/blood-2023-185157

Published: 2023

Journal Articles

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

L. Elizabeth Budde, Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Swetha Kambhampati, Alan Macias, Teresa Kim, Sylvia Dulan, Baishakhi Barva, Sandrine Puverel, Katrin Tiemann, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak

Blood (2023) 142 (Supplement 1): 221.

https://doi.org/10.1182/blood-2023-183032

Published: 2023

NARROW

A First-in-Human Dose Escalation Clinical Trial of Engineered Natural Killer Cell Therapy in Non-Small Cell Lung Cancer Patients Refractory to Immune Check Point Inhibitors

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Clonal Hematopoiesis and Venous Thromboembolism Risk in Lymphoma Patients Surviving Autologous Transplantation

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report

Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies - a BMT Survivor Study (BMTSS)

Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report

Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation

CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies - a BMT Survivor Study (BMTSS)

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only